MedTrace Logo

68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer

NCT03857087 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7

Last updated 2022-10-12

No results posted yet for this study

Summary

This trial studies how well gallium Ga 68-labeled prostate specific membrane antigen (PSMA)-11 (68Ga-PSMA) positron emission tomography (PET) works in patients with ovarian cancer to detect whether the tumor has spread to other places in the body. 68Ga-PSMA is a radioactive substance that binds to blood vessels around the ovarian cancer and can be imaged using PET. Diagnostic procedures, such as PET, may help find and diagnose find out how far the disease has spread.

Conditions

  • Ovarian Carcinoma

Interventions

DRUG

Gallium Ga 68-labeled PSMA-11

Given IV

PROCEDURE

Magnetic Resonance Imaging (MRI)

Given PET/MRI

PROCEDURE

Positron Emission Tomography (PET)

Undergo PET/MRI

Sponsors & Collaborators

Principal Investigators

  • Michael Ohliger, MD, PhD · University of California, San Francisco

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-02
Primary Completion
2022-06-30
Completion
2022-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03857087 on ClinicalTrials.gov